Natixis Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.7M | Buy |
46,869
+23,363
| +99% | +$849K | ﹤0.01% | 1138 |
|
|
2025
Q1 | $851K | Sell |
23,506
-27,404
| -54% | -$992K | ﹤0.01% | 1317 |
|
|
2024
Q4 | $2.14M | Sell |
50,910
-1,652
| -3% | -$69.5K | ﹤0.01% | 1075 |
|
|
2024
Q3 | $2.92M | Buy |
52,562
+39,086
| +290% | +$2.17M | 0.01% | 977 |
|
|
2024
Q2 | $554K | Sell |
13,476
-218
| -2% | -$8.96K | ﹤0.01% | 1413 |
|
|
2024
Q1 | $639K | Sell |
13,694
-1,595
| -10% | -$74.4K | ﹤0.01% | 1333 |
|
|
2023
Q4 | $731K | Buy |
15,289
+1,496
| +11% | +$71.5K | ﹤0.01% | 1302 |
|
|
2023
Q3 | $492K | Sell |
13,793
-1,957
| -12% | -$69.8K | ﹤0.01% | 1361 |
|
|
2023
Q2 | $727K | Buy |
15,750
+4,492
| +40% | +$207K | ﹤0.01% | 1242 |
|
|
2023
Q1 | $451K | Buy |
11,258
+1,016
| +10% | +$40.7K | ﹤0.01% | 1331 |
|
|
2022
Q4 | $475K | Buy |
+10,242
| New | +$475K | ﹤0.01% | 1304 |
|